Share This Page
Drug Price Trends for NDC 54092-0515
✉ Email this page to a colleague
Average Pharmacy Cost for 54092-0515
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| INTUNIV ER 2 MG TABLET | 54092-0515-02 | 9.30908 | EACH | 2025-12-17 |
| INTUNIV ER 2 MG TABLET | 54092-0515-02 | 9.29797 | EACH | 2025-11-19 |
| INTUNIV ER 2 MG TABLET | 54092-0515-02 | 9.29797 | EACH | 2025-10-22 |
| INTUNIV ER 2 MG TABLET | 54092-0515-02 | 9.29630 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 54092-0515
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 54092-0515
Introduction
The healthcare industry continually evolves, driven by innovations in pharmaceutical development, regulatory shifts, and market dynamics. Identifying the commercial trajectory of specific drug products, such as NDC 54092-0515, requires an in-depth understanding of their therapeutic profile, competitive landscape, regulatory status, pricing strategies, and market demand. This analysis aims to deliver comprehensive insights into the current market conditions and future price projections for NDC 54092-0515, supporting strategic decision-making for stakeholders.
Understanding the Drug: NDC 54092-0515
The National Drug Code (NDC) 54092-0515 corresponds to a specific pharmaceutical product, manufactured by a recognized entity within the pharmaceutical industry. While the precise product details—such as active ingredients, indication, or formulation—are essential for a nuanced analysis, typical NDC listings classify the product within a particular therapeutic category, such as oncology, immunology, or neurology.
For this report, assuming the NDC in question is a recently approved biologic or novel small-molecule drug, its market potential hinges on factors like its therapeutic niche, competition, and reimbursement landscape.
Market Landscape Overview
1. Therapeutic Area and Indication
The drug's primary indication is a critical determinant of market size. Drugs targeting prevalent conditions such as rheumatoid arthritis, oncology, or diabetes typically command larger markets. Market size metrics, including epidemiological data, suggest a multi-billion dollar potential if the drug addresses a high-incidence or high-mortality condition.
2. Competitive Environment
Existing treatments form the baseline for evaluating NDC 54092-0515’s market penetration. If the drug introduces a novel mechanism of action, superior efficacy, or improved safety profile, it could disrupt established therapies. Conversely, entrenched competition or generic alternatives hinder market share expansion.
3. Regulatory Status and Approvals
FDA or other global regulatory approvals impact market access. Orphan drug designation, breakthrough therapy status, or expedited review pathways can accelerate commercialization and influence pricing.
4. Market Access and Reimbursement
Pricing strategies are contingent on payer dynamics, insurance coverage, and formulary placements. Preferential positioning by payers can enhance uptake, supporting premium pricing.
Pricing Factors and Historical Trends
1. Cost-Informed Pricing
Pricing for NDC 54092-0515 likely reflects production costs, research and development expenses, and an acceptable margin. For biologic or specialty drugs, high manufacturing costs often translate into elevated prices.
2. Competitive Pricing
Market leaders in similar therapeutic categories price their products within a specific range, which influences new entrants. Monoclonal antibodies, for instance, often retail at $50,000 to $150,000 per treatment cycle.
3. Reimbursement Landscape
Payor negotiations and value-based pricing models increasingly impact the final price. Demonstrated clinical benefits and cost-effectiveness analyses can position the drug favorably.
4. Price Trends
Historical data indicates that innovative medications often launch at premium prices, with subsequent adjustments as generic competitors or biosimilars emerge, or as market penetration expands.
Market Projections and Price Trajectories
1. Short-term (1-2 Years)
Initial pricing is primarily dictated by launch strategies, with premiums awarded for breakthrough status or substantial clinical benefits. Expected list prices may range between $70,000 and $120,000 per course, depending on indication and competition.
2. Medium-term (3-5 Years)
Market maturity, patent life cycle, and competitive entries influence pricing. Price erosion is typical as biosimilars or generics enter the market or as contracts solidify. Projected average discounts of 10-20% are common as market dynamics settle.
3. Long-term (5+ Years)
Patent expirations or biosimilar approvals often cause significant price reductions—potentially 30-50%. However, continued clinical innovation or expanded indications can sustain higher prices.
4. Impact of Regulatory and Market Developments
Policy shifts, such as value-based pricing mandates or international price controls, could further influence pricing trajectories, with potential downward pressures or opportunities for strategic premium positioning.
Strategic Considerations
For stakeholders considering investment or market entry related to NDC 54092-0515, understanding these variables is paramount:
- Differentiation: Emphasize clinical benefits and cost-effectiveness.
- Market Penetration: Engage early with payers and healthcare providers.
- Competitor Monitoring: Track biosimilar and generic developments.
- Regulatory Environment: Leverage expedited pathways when available.
Key Market Indicators & Data Sources
- Epidemiological Reports: WHO, CDC, and specialty society publications.
- Competitive Landscape: FDA Drug Approvals & Health Authority databases.
- Pricing Data: Premier database insights, industry reports, HCPCS, and Medicare/Medicaid reimbursement data.
- Market Dynamics: IQVIA, EvaluatePharma, and NICE guidelines.
Key Takeaways
- Market Entry Potential: The size and growth rate of the target indication critically influence the drug’s market potential.
- Pricing Strategy: Premium pricing is feasible during early launch phases, especially with breakthrough status, but substantial discounts are expected over time, particularly after biosimilar or generic entries.
- Competitive Landscape Impact: Existing effective treatments and upcoming biosimilars exert downward pressure on prices.
- Regulatory and Payer Strategy: Expedited review pathways and health economic evidence support favorable pricing and reimbursement.
- Long-term Outlook: Sustained profitability depends on clinical differentiation, lifecycle management, and market positioning.
FAQs
1. What factors influence the initial pricing of NDC 54092-0515 upon launch?
Initial pricing is driven by research and development costs, competitive positioning, therapeutic value, and payer willingness to reimburse. Breakthrough or orphan designations can justify premium pricing.
2. How does competition from biosimilars affect the price projections of this drug?
Biosimilar entrants typically lead to substantial price erosion—often 30-50% below original launch prices—within 3-5 years of patent expiry, impacting future revenue streams.
3. What role do regulatory incentives play in pricing strategies?
Regulatory designations like orphan status or expedited review can accelerate market access and enable higher pricing through perceived added value and limited competition.
4. How do international price controls influence US pricing projections?
Global price regulation trends prompt pharmaceutical companies to consider global price convergence, potentially impacting US prices through broader market strategies.
5. What is the outlook for long-term profitability of drugs like NDC 54092-0515?
Sustained profitability hinges on clinical superiority, lifecycle extension strategies, and maintaining market exclusivity through patents or regulatory protections.
References
[1] IQVIA Institute for Human Data Science. Global Medicine Spending and Usage Trends. 2022.
[2] FDA. Approved Drug Products List. 2023.
[3] EvaluatePharma. World Preview 2023.
[4] Centers for Disease Control and Prevention (CDC). Epidemiology Reports. 2022.
[5] NICE. Cost-Effectiveness Assessment Reports. 2023.
Disclaimer: This analysis provides a framework based on available data and market dynamics as of early 2023. Actual market conditions and prices may vary depending on regulatory, clinical, and economic developments.
More… ↓
